Intelligence Search Intelligence Filter by: Industry Team Airport & AviationAutomotiveEmerging TechnologiesEnergy Food & BeverageHealth CareHospitality, Resort & GolfInsurance & Reinsurance Life SciencesMedical DevicesSports Practice Area Business Law All Business LawEmployee Benefits & Executive CompensationEnvironmental RegulationEstates & TrustsFinance & Financial InstitutionsHealth Care Finance Private Equity & Venture CapitalPublic FinanceReal EstateSecurities, Commodities & Exchange RegulationTaxationTransactional & Securities Government & Public Policy All Government & Public PolicyFDA RegulatoryGovernment ProcurementImmigration, Nationality & Consular Law NHTSA & Motor Vehicle SafetyPolitical LawPublic PolicySurface Transport Intellectual Property All Intellectual PropertyBusiness Method & Software PatentsChemical, Biotechnology & PharmaceuticalElectronicsGreen Energy TechnologiesInformation Technology & Outsourcing IP Due DiligenceIP LitigationMechanical & Electromechanical TechnologiesPatent Office TrialsTrademark, Copyright & Advertising Counseling International All InternationalChina EuropeJapan Litigation All LitigationAntitrustAppellateBankruptcy & Business ReorganizationsBusiness Litigation & Dispute ResolutionConstructionConsumer Financial Services Distribution & FranchiseGovernment Enforcement, Compliance & White Collar DefenseInsurance & Reinsurance LitigationLabor & EmploymentPrivacy, Security & Information ManagementSecurities Enforcement & LitigationTrade Secret Noncompete Litigation Topic Accountable Care OrganizationsAmerica Invents Act (Patent Reform)Consumer Protection Act Corporate GovernanceDodd–Frank Wall Street ReformExport Control/Economic Sanctions Foreign Corrupt Practices Act (FCPA)Health Care ReformPersonalized Medicine Type ArticleBlog Post BookNewsletter VideoWhite Paper Featured All Filters applied: Search phrase entered: Sort results by: Most Recent Most Viewed Most Shared Foley Blogs: CFSL Bulletin Cleantech & Nano Dashboard Insights Labor & Employment Law Perspectives Personalized Medicine Bulletin PharmaPatents Renewable Energy Outlook Wisconsin Appellate Law 123next Akami Technologies, Inc. v. Limelight Networks, Inc.: Revisiting the Rules for Joint Infringement 22 April 2011 Article By Marshall J. Brown, Foley & Lardner LLP This article is part of our Spring 2011 edition of Legal News: China Quarterly Newsletter, Eye on China. On December 20,... Bilski's Impact on Biotech and Pharmaceutical Method Claims 22 April 2011 Article By Pei Wu and James F. Ewing, Foley & Lardner LLP This article is part of our Spring 2011 edition of Legal News: China Quarterly Newsletter, Eye on China. In the... 2011 Patent Reform Act Signed by President Obama on September 16, 2011 16 September 2011 On September 16, 2011, President Obama signed the Leahy-Smith America Invents Act into law. As outlined below, several important changes take effect... Deja Vu All Over Again in Federal Circuit's August 16 Myriad Decision 17 August 2012 PharmaPatents On August 16, 2012, just four weeks after it heard oral arguments, the Federal Circuit issued its second decision in Association for Molecular Pathology v. Myriad... Eli Lilly Suggests Bright-Line Rule In Myriad Amicus Brief 20 June 2012 PharmaPatents Eli Lilly filed an interesting amicus brief in the remand of Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI case).... En Banc Federal Circuit Eases Requirements for Induced Infringement of Method Claims 04 September 2012 PharmaPatents On August 31, 2012, the Federal Circuit issued an en banc, per curiam opinion deciding both Akamai Technologies, Inc. v. Limelight Networks, Inc. and McKesson Technologies,... Federal Circuit Decides Highly Anticipated "ACLU/Myriad" Gene Patenting Case — Subject Matter Patent-Eligibility of Isolated DNA and Diagnostic Methods Addressed Head-On 29 July 2011 Legal News Alert: Life Sciences On July 29, 2011, in one of the most controversial and publicized biotech patent cases in many years, the Federal Circuit decided the “ACLU/Myriad” gene patenting... Federal Circuit Reverses Course on Classen, Finds That Many Method Claims Satisfy 35 USC § 101, Safe Harbor of 35 USC § 271(e)(1) Does Not Shelter Many Defendants 31 August 2011 Legal News Alert: Intellectual Property On August 31, 2011, the Federal Circuit issued its second decision in Classen Immunotherapies, Inc. v. Biogen Idec (App. 2006-1643, -1649), on remand from the Supreme... Federal Circuit Revisits the Patent-Eligibility Test After Bilski 22 April 2011 Article By Alex Nie, Foley & Lardner LLP This article is part of our Spring 2011 edition of Legal News: China Quarterly Newsletter, Eye on China. The U.S. Supreme Court... Federal Circuit Sets Briefing Deadline, Oral Argument Date For Myriad Isolated DNA Case 01 May 2012 PharmaPatents Pursuant to the Supreme Court’s March 26, 2012 order remanding Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI... 123next Related 1 2 3
Akami Technologies, Inc. v. Limelight Networks, Inc.: Revisiting the Rules for Joint Infringement 22 April 2011 Article By Marshall J. Brown, Foley & Lardner LLP This article is part of our Spring 2011 edition of Legal News: China Quarterly Newsletter, Eye on China. On December 20,...
Bilski's Impact on Biotech and Pharmaceutical Method Claims 22 April 2011 Article By Pei Wu and James F. Ewing, Foley & Lardner LLP This article is part of our Spring 2011 edition of Legal News: China Quarterly Newsletter, Eye on China. In the...
2011 Patent Reform Act Signed by President Obama on September 16, 2011 16 September 2011 On September 16, 2011, President Obama signed the Leahy-Smith America Invents Act into law. As outlined below, several important changes take effect...
Deja Vu All Over Again in Federal Circuit's August 16 Myriad Decision 17 August 2012 PharmaPatents On August 16, 2012, just four weeks after it heard oral arguments, the Federal Circuit issued its second decision in Association for Molecular Pathology v. Myriad...
Eli Lilly Suggests Bright-Line Rule In Myriad Amicus Brief 20 June 2012 PharmaPatents Eli Lilly filed an interesting amicus brief in the remand of Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI case)....
En Banc Federal Circuit Eases Requirements for Induced Infringement of Method Claims 04 September 2012 PharmaPatents On August 31, 2012, the Federal Circuit issued an en banc, per curiam opinion deciding both Akamai Technologies, Inc. v. Limelight Networks, Inc. and McKesson Technologies,...
Federal Circuit Decides Highly Anticipated "ACLU/Myriad" Gene Patenting Case — Subject Matter Patent-Eligibility of Isolated DNA and Diagnostic Methods Addressed Head-On 29 July 2011 Legal News Alert: Life Sciences On July 29, 2011, in one of the most controversial and publicized biotech patent cases in many years, the Federal Circuit decided the “ACLU/Myriad” gene patenting...
Federal Circuit Reverses Course on Classen, Finds That Many Method Claims Satisfy 35 USC § 101, Safe Harbor of 35 USC § 271(e)(1) Does Not Shelter Many Defendants 31 August 2011 Legal News Alert: Intellectual Property On August 31, 2011, the Federal Circuit issued its second decision in Classen Immunotherapies, Inc. v. Biogen Idec (App. 2006-1643, -1649), on remand from the Supreme...
Federal Circuit Revisits the Patent-Eligibility Test After Bilski 22 April 2011 Article By Alex Nie, Foley & Lardner LLP This article is part of our Spring 2011 edition of Legal News: China Quarterly Newsletter, Eye on China. The U.S. Supreme Court...
Federal Circuit Sets Briefing Deadline, Oral Argument Date For Myriad Isolated DNA Case 01 May 2012 PharmaPatents Pursuant to the Supreme Court’s March 26, 2012 order remanding Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI...